Subscribe
epilepsy-istock-636332090-sudok1-
sudok1 / iStockphoto.com
27 March 2017Americas

PTAB upholds anti-epileptic drug patent

The Patent Trial and Appeal Board (PTAB) has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat (lacosamide) in a case brought by Argentum Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circuit rules against Mylan in patent dispute over epilepsy drug
4 February 2019   Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Fed Circuit rules against Mylan in patent dispute over epilepsy drug
4 February 2019   Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.

More on this story

Americas
Fed Circuit rules against Mylan in patent dispute over epilepsy drug
4 February 2019   Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims